What is Zenith Epigenetics?
Zenith Epigenetics operates at the intersection of molecular biology and clinical oncology, specializing in the discovery and development of BET inhibitors. The company's core mission is to translate complex bromodomain biology into actionable, targeted therapeutics that can overcome the pervasive issue of drug resistance in various cancer types. Their lead candidate, ZEN-3694, serves as the cornerstone of their pipeline, currently undergoing evaluation in clinical trials to determine its efficacy in combination therapy settings. By collaborating with leading oncology research institutions, Zenith Epigenetics is building a robust framework for addressing unmet medical needs, aiming to improve patient outcomes through precision medicine and innovative pharmacological interventions.
How much funding has Zenith Epigenetics raised?
Zenith Epigenetics has raised a total of $12.3M across 2 funding rounds:
Unspecified
$8M
Private Equity
$4.3M
Unspecified (2014): $8M, investors not publicly disclosed
Private Equity (2014): $4.3M, investors not publicly disclosed
Key Investors in Zenith Epigenetics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Zenith Epigenetics?
With the recent strategic investment, Zenith Epigenetics is well-positioned to accelerate its clinical development programs and expand its research footprint. The primary focus for the upcoming fiscal periods will likely involve the advancement of ZEN-3694 through late-stage clinical milestones and the potential expansion of its pipeline into additional therapeutic indications. As the company continues to refine its combination therapy strategies, the emphasis will remain on demonstrating superior clinical efficacy compared to standard-of-care treatments. Investors and industry stakeholders will be closely monitoring the data readouts from ongoing trials, as these results will be pivotal in determining the company's long-term commercial viability and its potential for future strategic partnerships or acquisition within the broader biotechnology landscape.
See full Zenith Epigenetics company page
